Innovent Biologics Inc. and Eli Lilly & Co. said the U.S. Food and Drug Administration is currently planning to hold an advisory committee meeting to discuss their biologics license application for sintilimab injection. "FDA Accepts Innovent, Eli Lilly Application for Sintilimab," published at 6:27 a.m. ET, incorrectly reported in the second paragraph that the agency isn't planning such a meeting.

 

(END) Dow Jones Newswires

May 18, 2021 09:47 ET (13:47 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Eli Lilly Charts.